NASS v. MAINE BOARD OF LICENSURE IN MEDICINE

CourtDistrict Court, D. Maine
DecidedJuly 24, 2024
Docket1:23-cv-00321
StatusUnknown

This text of NASS v. MAINE BOARD OF LICENSURE IN MEDICINE (NASS v. MAINE BOARD OF LICENSURE IN MEDICINE) is published on Counsel Stack Legal Research, covering District Court, D. Maine primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
NASS v. MAINE BOARD OF LICENSURE IN MEDICINE, (D. Me. 2024).

Opinion

UNITED STATES DISTRICT COURT

DISTRICT OF MAINE

MERYL J. NASS, M.D., ) ) Plaintiff, ) ) V. ) 1:23-cv-00321-LEW ) MAINE BOARD OF LICENSURE ) IN MEDICINE et al., ) ) Defendants.

ORDER ON DEFENDANTS’ MOTION TO DISMISS

The Maine Board of Licensure in Medicine (the “Board”) conducted disciplinary proceedings against Meryl J. Nass, M.D., for making public statements about COVID-19, its treatment, and the federal response to the pandemic that were inconsistent with its stated position barring physicians from spreading “COVID-19 vaccine misinformation.” Complaint ¶ 17 (ECF No. 1). The Board suspended Dr. Nass’s license to practice medicine during those proceedings, which are ongoing. Nass initiated this matter to bring federal and state constitutional claims and a state statutory claim against the Board and several of its members (the “Individual Defendants”).1 The matter is now before the Court on the Defendants’ Motion to Dismiss (ECF No. 14). Because Younger abstention restrains me from exercising jurisdiction over this matter while the Board’s disciplinary proceedings

1 The Individual Defendants are: Maroulla S. Gleaton, M.D.; Holly Fanjoy, M.D.; Noah Nesin, M.D.; Renee Fay-LeBlanc, M.D.; Brad E. Waddell, M.D.; Gregory Jamison, RPh; Noel Genova, PA; Lynne M. Weinstein; and Susan Dench. remain ongoing, I grant in part the Defendants’ Motion, as outlined in the conclusion of this order.

BACKGROUND This background narrative is drawn principally from the Complaint and its attachments, and the allegations found in the Complaint are taken as true for the purpose of evaluating the motion to dismiss. García-Catalán v. United States, 734 F.3d 100, 102 (1st Cir. 2013); see also Trans-Spec Truck Serv., Inc. v. Caterpillar, Inc., 524 F.3d 315, 321 (1st Cir. 2008) (“Exhibits attached to the complaint are properly considered part of the

pleading ‘for all purposes,’ including Rule 12(b)(6).” (quoting Fed. R. Civ. P. 10(c))); cf. Gonzalez v. United States, 284 F.3d 281, 288 (1st Cir. 2002) (“The attachment of exhibits to a Rule 12(b)(1) motion does not convert it to a Rule 56 motion.”). The background narrative is also informed by information related to the progress of the state proceedings, provided by the Office of the Maine Attorney General in advance of oral argument on the

Motion to Dismiss. (See ECF No. 20.) Meryl J. Nass is a medical doctor who resides in Ellsworth, Maine. The Maine Board of Licensure in Medicine first licensed Dr. Nass to practice medicine in 1997. During the pandemic, Nass commented publicly about subjects related to COVID-19. She criticized the government’s handling of the pandemic, including what she viewed as the

“suppression of effective medications to treat COVID-19,” like ivermectin and hydroxychloroquine. Compl. ¶ 30. Nass also questioned the safety of vaccines and the efficacy of mask mandates. Nass disseminated her opinions online, through her blog and on Twitter, over the radio, in testimony to state legislatures, and in conversation with other state-level officials.

In the fall of 2021, the Board issued a “Position Statement” explaining that licensees could face disciplinary action for spreading “misinformation and disinformation” about COVID-19 vaccines. Compl. ¶ 17. The Position Statement endorsed a statement issued by the Federation of State Medical Boards (“FSMB”)2 that identified license suspension and revocation as potential consequences for spreading COVID-19 misinformation. The Position Statement also featured several links to “resources for physicians [from the

American Medical Association] that explain how to counter misinformation, and why it is important to do so.” Compl. ¶ 17. The viewpoints that Nass expressed about COVID-19 frequently “conflicted with those asserted in the Position Statement and the resources the Position Statement identifies as useful.” Compl. ¶ 31. On or about October 26, 2021, the Board received a complaint that Nass was

spreading misinformation in a video and on her website. A day later, the Board issued a notice of complaint to Nass and directed her to respond.3 The Board received a second

2 The Complaint describes the Federation of State Medical Boards as a “private organization with no regulatory authority and its own private agenda” and explains that the Chair of the Maine Board of Licensure in Medicine has “close ties” to the organization, including a “policy-setting leadership position.” Compl. ¶¶ 23, 25, 101. The Chair of the Board has twice denied requests to disqualify herself from Nass’s disciplinary proceedings. 3 After receiving the notice, Nass questioned the Board’s authority to investigate the complaint, which she characterizes as focusing on “a statement made in her private life.” Compl. ¶ 35. An Investigative Secretary for the Board responded in part as follows: The basis here for the Board’s jurisdiction is that there is alleged unprofessional conduct, particularly where you have communicated in your capacity as a physician in the interview and on the website that could allow for patients and the public to view the information you provide as misleading and/or inaccurate. Compl. Ex. 1 at 1 (ECF No. 1-1). complaint about Nass on November 7, 2021. Supplementing those complaints were notes, prepared and submitted by attorneys at the Office of the Maine Attorney General,

summarizing Nass’s comments before the Maine Board of Pharmacy on November 7, 2021, urging it to reconsider guidance on dispensing ivermectin. The Defendant Board met in executive session on January 11, 2022, with Nass attending as an observer. The Board discussed the two complaints against Nass, which one Board member, Defendant Fay-LeBlanc, summarized as “focus[ing on] unprofessional conduct due to the spreading of misinformation about COVID-19—primarily on social

media.” Compl. ¶ 49. The Board also discussed three new “Assessment and Direction” matters concerning Nass: two arising from mandated reports from health providers and a third involving a communication from Nass to the Board.4 Compl. ¶ 48. The Board voted unanimously to “further investigate” the allegations by, among other things, directing Nass to undergo a neuropsychological evaluation (Compl. Ex. 2; ECF No. 1-2);5 suspending her

4 The Complaint describes the three Assessment and Direction matters as follows: The three [Assessment and Direction] matters involved (1) receipt of a mandated report from a physician reporting the hospitalization of a patient Dr. Nass allegedly “diagnosed over the phone”; (2) Dr. Nass’s communication to the [Board] that she had been forced to provide misinformation to a pharmacist who had demanded to know the reason she prescribed hydroxychloroquine to Patient 2; and (3) a mandated report from a certified nurse midwife complaining about Dr. Nass having issued a prescription to a patient without consulting the certified nurse midwife. Compl. ¶ 51. 5 The Board issued the Order Directing Evaluation pursuant to a Maine statute that provides in part: Upon its own motion or upon complaint, the board, in the interests of public health, safety and welfare, shall treat as an emergency a complaint or allegation that an individual licensed under this chapter is or may be unable to practice medicine with reasonable skill and safety to patients by reason of mental illness, alcohol intemperance, excessive use of drugs, narcotics or as a result of a mental or physical condition interfering with the medical license (Compl. Ex. 3; ECF No. 1-3); subpoenaing patient records (Compl. Ex. 4; ECF No. 1-4); requesting that Nass answer written questions about the complaints that the

Board received (Compl. Ex. 5; ECF No. 1-5); and issuing a complaint of its own against Nass as to the three Assessment and Direction matters. Compl.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Morgan
313 U.S. 409 (Supreme Court, 1941)
Chaplinsky v. New Hampshire
315 U.S. 568 (Supreme Court, 1942)
Bantam Books, Inc. v. Sullivan
372 U.S. 58 (Supreme Court, 1963)
Younger v. Harris
401 U.S. 37 (Supreme Court, 1971)
Huffman v. Pursue, Ltd.
420 U.S. 592 (Supreme Court, 1975)
Withrow v. Larkin
421 U.S. 35 (Supreme Court, 1975)
Imbler v. Pachtman
424 U.S. 409 (Supreme Court, 1976)
Ohio Bureau of Employment Services v. Hodory
431 U.S. 471 (Supreme Court, 1977)
Butz v. Economou
438 U.S. 478 (Supreme Court, 1978)
Moore v. Sims
442 U.S. 415 (Supreme Court, 1979)
Kentucky v. Graham
473 U.S. 159 (Supreme Court, 1985)
Malley v. Briggs
475 U.S. 335 (Supreme Court, 1986)
Pennzoil Co. v. Texaco Inc.
481 U.S. 1 (Supreme Court, 1987)
Hunter v. Bryant
502 U.S. 224 (Supreme Court, 1991)
Antoine v. Byers & Anderson, Inc.
508 U.S. 429 (Supreme Court, 1993)
Buckley v. Fitzsimmons
509 U.S. 259 (Supreme Court, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
NASS v. MAINE BOARD OF LICENSURE IN MEDICINE, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nass-v-maine-board-of-licensure-in-medicine-med-2024.